The Fed left the federal funds target at 3.50%-3.75% on April 29, but the real signal was a four-way dissent that exposed a deep split over how quickly policy should pivot. Energy-driven inflation risk is now colliding with softer labor momentum inside the Committee.
GE HealthCare $GEHC fell 9% after cutting 2026 adjusted EPS guidance to $4.80-$5.00 from $4.95-$5.15. Revenue still rose 7.4% to $5.13 billion, but margins were hit by a supplier issue and higher memory-chip, oil, and freight costs.
UBS $UBS rose 5% after first-quarter net profit jumped 80% to $3.0 billion, beating the $2.8 billion LSEG consensus. The bank kept a 14.7% CET1 ratio and said it is still on track to complete $3 billion of buybacks by second-quarter results.
Kone $KNEBV agreed to buy TK Elevator for 29.4 billion euros ($34.4 billion), a deal that would create the world's largest elevator maker. Thyssenkrupp shares rose 8%, while Kone said the combination could deliver EUR 700 million of annual run-rate synergies.
Brent pushed above $114 after the UAE said it will leave OPEC and OPEC+ on May 1, removing the cartel's third-largest producer at a time of disrupted Hormuz shipping. Abu Dhabi framed the move as a capacity decision, not a break with oil-market stability.
The Bank of Japan kept the overnight call-rate target at around 0.75% in a 6-3 vote and lifted its FY2026 core CPI view to 2.5%-3.0%. The April outlook said an oil shock tied to the Middle East would slow growth in 2026 even as inflation risks skew upward.
General Motors $GM raised 2026 EBIT-adjusted guidance to $13.5B-$15.5B after first-quarter EBIT-adjusted rose 21.9% to $4.253B. A favorable tariff adjustment of about $500M lowered expected 2026 gross tariff costs to $2.5B-$3.5B.
Qualcomm $QCOM rose to $148.85, up $15.01 or about 11.2%, after analyst Ming-Chi Kuo said OpenAI is working with Qualcomm and MediaTek on smartphone processors for a 2028 device. None of the companies confirmed the report, but the move put Qualcomm back at the center of the AI hardware trade.
HawkEye 360 $HAWK is marketing 16 million shares at $24 to $26, implying a valuation of up to $2.42B and gross proceeds of as much as $416M. The listing would bring a 30-plus-satellite radio-frequency intelligence specialist to the NYSE as the 2026 IPO window reopens.
RE/MAX $RMAX rose about 22% after The Real Brokerage $REAX agreed to buy the company in a cash-and-stock transaction valuing it at about $880M. The combined group says it would have generated roughly $2.3B of 2025 revenue and $157M of adjusted EBITDA before synergies.
Organon $OGN rose about 31% before the bell after Sun Pharma $SUNPHARMA agreed to pay $14 a share in cash, valuing the target at $11.75B including debt. Sun said the combination would create a $12.4B-revenue pharma group with a larger women’s-health and biosimilars footprint.
Shell $SHEL agreed to buy ARC Resources $ARX for $16.4B, adding about 370,000 boe/d and roughly 2 billion boe of reserves. The cash-and-stock deal is set to lift Shell's production CAGR through 2030 to 4% and add about $250M of annualized synergies within a year of closing.